The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N.

Disclosed are devices for determining an analyte concentration (e.g., glucose). The devices comprise a sensor configured to generate a signal associated with a concentration of an analyte and a sensing membrane located over the sensor. The sensing membrane comprises an enzyme layer, wherein the enzyme layer comprises an enzyme and a polymer comprising polyurethane and/or polyurea segments and one or more zwitterionic repeating units. The enzyme layer protects the enzyme and prevents it from leaching from the sensing membrane into a host or deactivating.

Disclosed are devices for determining an analyte concentration (e.g., glucose). The devices comprise a sensor configured to generate a signal associated with a concentration of an analyte and a sensing membrane located over the sensor. The sensing membrane comprises an enzyme layer, wherein the enzyme layer comprises an enzyme and a polymer comprising polyurethane and/or polyurea segments and one or more zwitterionic repeating units. The enzyme layer protects the enzyme and prevents it from leaching from the sensing membrane into a host or deactivating.

The present application relates to a combination therapy for treatment of inflammatory diseases comprising an immunomodulator compound and a GABA-receptor agonist in an amount effective to reduce inflammation and ameliorate disease. In certain embodiments, the present application relates to treatment of T1D by administering an immunomodulator compound and a GABA-receptor agonist in an amount effective to prevent, reduce, and/or treat hyperglycemia in the human or animal subject. In certain embodiments, the immunomodulator compound and GABA-receptor agonist are administered in an amount effective to control autoimmune responses and safely increase β-cell mass and function in the context of established β-cell autoimmunity.

The present application relates to a combination therapy for treatment of inflammatory diseases comprising an immunomodulator compound and a GABA-receptor agonist in an amount effective to reduce inflammation and ameliorate disease. In certain embodiments, the present application relates to treatment of T1D by administering an immunomodulator compound and a GABA-receptor agonist in an amount effective to prevent, reduce, and/or treat hyperglycemia in the human or animal subject. In certain embodiments, the immunomodulator compound and GABA-receptor agonist are administered in an amount effective to control autoimmune responses and safely increase β-cell mass and function in the context of established β-cell autoimmunity.

The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I)

##STR00001##

which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I)

##STR00001##

which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

This application describes modified amino acids and polypeptides comprising a SO.sub.2F or CH.sub.2CH.sub.2SO.sub.2F group bound to the side chain of an amono acid or amino acid residue of a polypeptide in place of a hydrogen of a hydroxyl or amino substituent thereof. Methods of covalently binding the polypeptides to receptot sites of receptor proteins are also described herein.

This application describes modified amino acids and polypeptides comprising a SO.sub.2F or CH.sub.2CH.sub.2SO.sub.2F group bound to the side chain of an amono acid or amino acid residue of a polypeptide in place of a hydrogen of a hydroxyl or amino substituent thereof. Methods of covalently binding the polypeptides to receptot sites of receptor proteins are also described herein.

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof and a second active ingredient which has an anti-epileptic effect, or a pharmaceutically acceptable salt thereof.